Re: Results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (PREFERE trial)

The authors of this “Letter to the Editors” express their major concern about selective and biased reporting in this paper.

Detalles Bibliográficos
Autores principales: Boehle, Andreas, Kahmann, Frank, Henkel, Thomas Oliver, Zimmermann, Joerg, Machtens, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954738/
https://www.ncbi.nlm.nih.gov/pubmed/33507360
http://dx.doi.org/10.1007/s00432-020-03499-x
_version_ 1783664137503506432
author Boehle, Andreas
Kahmann, Frank
Henkel, Thomas Oliver
Zimmermann, Joerg
Machtens, Stefan
author_facet Boehle, Andreas
Kahmann, Frank
Henkel, Thomas Oliver
Zimmermann, Joerg
Machtens, Stefan
author_sort Boehle, Andreas
collection PubMed
description The authors of this “Letter to the Editors” express their major concern about selective and biased reporting in this paper.
format Online
Article
Text
id pubmed-7954738
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-79547382021-03-28 Re: Results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (PREFERE trial) Boehle, Andreas Kahmann, Frank Henkel, Thomas Oliver Zimmermann, Joerg Machtens, Stefan J Cancer Res Clin Oncol Letter to the Editor The authors of this “Letter to the Editors” express their major concern about selective and biased reporting in this paper. Springer Berlin Heidelberg 2021-01-28 2021 /pmc/articles/PMC7954738/ /pubmed/33507360 http://dx.doi.org/10.1007/s00432-020-03499-x Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Letter to the Editor
Boehle, Andreas
Kahmann, Frank
Henkel, Thomas Oliver
Zimmermann, Joerg
Machtens, Stefan
Re: Results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (PREFERE trial)
title Re: Results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (PREFERE trial)
title_full Re: Results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (PREFERE trial)
title_fullStr Re: Results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (PREFERE trial)
title_full_unstemmed Re: Results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (PREFERE trial)
title_short Re: Results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (PREFERE trial)
title_sort re: results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (prefere trial)
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954738/
https://www.ncbi.nlm.nih.gov/pubmed/33507360
http://dx.doi.org/10.1007/s00432-020-03499-x
work_keys_str_mv AT boehleandreas reresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial
AT kahmannfrank reresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial
AT henkelthomasoliver reresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial
AT zimmermannjoerg reresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial
AT machtensstefan reresultsofarandomizedtrialoftreatmentmodalitiesinpatientswithloworearlyintermediateriskprostatecancerpreferetrial

Ejemplares similares